HHS Carcinogen Report Updated to Include 8 Substances
The US Department of HHS added 8 new substances to the 15th Report on Carcinogens, bringing the total list to 256 substances.
Hyperacidity/GERD/Ulcers
Phathom Seeks Approval of Vonoprazan-Based Regimens for H. Pylori Infection
The applications are based on data from the phase 3 PHALCON-HP trial.
PPI Use May Increase Risk of Community-Acquired Pneumonia
Increased incidence of CAP was noted in stroke patients using PPIs.
Non-Antimicrobial Drugs Tied to Drug-Resistant Bacterial Infection
Proton pump inhibitors, beta-blockers, antimetabolites linked to infection with antibiotic-resistant bacteria
Add-On PPI Therapy May Improve Glycemic Control in Diabetes
However, treatment with proton pump inhibitors is not associated with risk for incident diabetes in the general population
Study Shows Vonoprazan-Based Regimens Noninferior to PPI-Based Triple Therapy
Vonoprazan is an oral small molecule potassium-competitive acid blocker.
Proton Pump Inhibitor Use Linked to Asthma Risk in Children
Findings showed that children who were initiated on PPIs were 57% more likely to be diagnosed with asthma.
OTC Medicines Containing “Clean” Inactive Ingredients Launched
Genexa has launched 4 over-the-counter (OTC) medicines that contain no artificial ingredients.
Proton Pump Inhibitor Use Linked to Increased Diabetes Risk
Type 2 diabetes risk increased with increasing length of PPI use, particularly use for more than two years.
Clinical Program for Investigational GERD Drug Discontinued
The bile acid sequestrant was designed to be maintained in the stomach over an extended period of time where it was expected to intercept bile before it reached the esophagus.
